Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
Fiona McPhee(Bristol-Myers Squibb (United States)), Paul M. Scola(Bristol-Myers Squibb (United States)), Paul Falk(Bristol-Myers Squibb (United States)), Li‐Qiang Sun(Bristol-Myers Squibb (United States)), Susan Chaniewski(Bristol-Myers Squibb (United States)), Steven M. LeVine(Kaiser Permanente Oakland Medical Center), Jacques Friborg(Bristol-Myers Squibb (United States)), Richard J. Colonno(Assembly Biosciences (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Guangzhi Zhai(Bristol-Myers Squibb (United States)), Diana Barry(Bristol-Myers Squibb (United States)), Michael Sinz(Rutgers, The State University of New Jersey), Fei Yu(Yunnan Academy of Agricultural Sciences), Dennis Hernandez(Bristol-Myers Squibb (United States)), Min S. Lee(University of California, Los Angeles), Amy K. Sheaffer(Bristol-Myers Squibb (United States)), Kathy Mosure(Bristol-Myers Squibb (United States)), Chaoqun Chen(Bristol-Myers Squibb (United States)), Jay O. Knipe(Bristol-Myers Squibb (United States))
Cited by 186
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes
|Drug Metabolism and Disposition|2002|447
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414